S-ketamine in patient-controlled analgesia with oxycodone improves analgesia in a dose-

dependent manner after major lumbar fusion surgery: a randomized, double-blind,

placebo-controlled clinical trial

Elina C.V. Brinck[1,2,#a ¶], Taru Virtanen[3,¶, #b], Sanna Mäkelä[4], Venla Soini[5], Ville-Veikko

Hynninen[4], Jukka Mulo[4], Urmas Savolainen[4], Juho Rantakokko[5], Kreu Maisniemi[1], Antti

Liukas[3], Klaus T. Olkkola[2], Vesa Kontinen[6], Pekka Tarkkila[1], Marko Peltoniemi[3], Teijo I.

Saari[3,4, #b]

[1]Department of Anaesthesiology, Töölö Hospital, Division of Anaesthesiology, Intensive Care
and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki,
Finland

[2]Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University of
Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

[3]Department of Anaesthesiology and Intensive Care, University of Turku, Turku, Finland

[4]Division of Perioperative Services, Intensive Care Medicine and Pain Management; Turku
University Hospital

[5]Division of the musculoskeletal system at Turku University Hospital, Turku University
Hospital, Department of Orthopaedics, University of Turku, Turku, Finland.

[6]Department of Anaesthesiology, Jorvi Hospital, Division of Anaesthesiology, Intensive Care
and Pain Medicine, University of Helsinki and HUS Helsinki University Hospital, Helsinki,
Finland

[#a] Current address: Department of Anesthesiology, Töölö Hospital, HUS Helsinki University
Hospital, Helsinki, Finland

[#b] Current address: Department of Anaesthesiology and Intensive Care, University of Turku,
Turku, Finland

* Corresponding author

Email: teisaa@utu.fi (TIS)

Abstract

BACKGROUND: Spinal fusion surgery causes severe pain. Strong opioids, commonly used as

postoperative analgesics, may have unwanted side effects. S-ketamine may be an effective

analgesic adjuvant in opioid patient-controlled analgesia (PCA). However, the optimal adjunct S-

ketamine dose to reduce postoperative opioid consumption is still unknown.

METHODS: We randomized 107 patients at two tertiary hospitals in a double-blinded, placebo-

controlled clinical trial of adults undergoing major lumbar spinal fusion surgery. Patients were

randomly allocated to four groups in order to compare the effects of three different doses of

adjunct S-ketamine (0.25, 0.5, and 0.75 mg ml-1) or placebo on postoperative analgesia in

oxycodone PCA. Study drugs were administered for 24 hours postoperative after which

oxycodone-PCA was continued for further 48 hours. Our primary outcome was cumulative

oxycodone consumption at 24 hours after surgery.

RESULTS: Of the 100 patients analyzed, patients receiving 0.75 mg ml^{-1} S-ketamine in

oxycodone PCA needed 25% less oxycodone at 24 h postoperatively (61.2 mg) compared with

patients receiving 0.5 mg ml^{-1} (74.7 mg) or 0.25 mg ml^{-1} (74.1 mg) S-ketamine in oxycodone or

oxycodone alone (81.9 mg) (mean difference: -20.6 mg; 95% confidence interval [CI]: -41 to -

0.20*; P* = 0.048). A significant beneficial effect in mean change of pain intensity at rest was seen

in the group receiving 0.75 mg ml^{-1} S-ketamine in oxycodone PCA compared with patients

receiving lower ketamine doses or oxycodone alone (standardized effect size: 0.17, 95% CI:

0.013–0.32, *P* = 0.033). The occurrence of adverse events was similar among the groups.

CONCLUSIONS: Oxycodone PCA containing S-ketamine as an adjunct at a ratio of 1: 0.75

decreased cumulative oxycodone consumption at 24 h after major lumbar spinal fusion surgery

without additional adverse effects.

Introduction

Severe postoperative pain is common after major spinal fusion surgery.[1] Inadequate pain management is associated with increased postoperative complications, delayed ambulation, and chronic postoperative pain.[2] This may lead to unplanned readmission after surgery, decreased patient satisfaction, and increased health-care costs. Opioids have been the cornerstone of postoperative analgesia after major surgery, but the increasing awareness of the problems associated with their use, such as opioid-associated adverse effects, opioid-induced hyperalgesia, and the risk of addiction, combined with the current opioid crisis has encouraged the search for alternative analgesic strategies.

Multimodal analgesia targets different pain signaling pathways by combining two or more analgesic modalities, aiming at additive or even synergistic analgesic effect.[3] Multimodal analgesia has proven feasible after major spinal fusion surgery in an effort to optimize pain relief while minimizing opioid-related adverse effects.[4,5]

Patient-controlled analgesia (PCA) use is associated with lower pain intensity and greater patient satisfaction compared with conventional (oral, subcutaneous, or intramuscular) administration routes.[6] PCA may enhance patient autonomy because the analgesic drug is readily available. Morphine is the most frequently used opioid in PCA, while oxycodone use is associated with higher patient satisfaction scores.[6,7]

Low-dose (<1 mg kg^{-1}) ketamine inhibits N-methyl-D-aspartate receptors in nociceptive neurons and activates descending inhibitory pain pathways, resulting in attenuated wind up and central sensitization.[8-11] The effect of perioperative intravenous ketamine as an adjunct analgesic has been documented in several clinical trials and meta-analyses.[12] A recent review article concluded

that combining ketamine with an opioid in IV-PCA during the postoperative period has a

beneficial effect on analgesia and opioid consumption.[13] In orthopedic surgery, earlier trials

found negative or unclear results with opioid-ketamine PCA.[14-16] However, studies' vast

heterogeneity and small sample sizes have failed to establish a possible a possible dose-

responsiveness. Thus, the optimal ketamine to opioid ratio in intravenous PCA is yet to be

elucidated.

We hypothesized that adjunct S-ketamine with oxycodone in an intravenous PCA is superior to

oxycodone, with reduced opioid-associated adverse events in the immediate postoperative period

after major spinal surgery. This randomized, double-blind, placebo-controlled study compared

three different doses of S-ketamine with placebo added as an adjuvant to oxycodone IV-PCA

administered for 24 hours after lumbar spinal fusion in adult patients. After the study phase, IV

oxycodone-PCA without ketamine was continued for further 48 hours. The primary outcome was

cumulative oxycodone consumption at 24 h after surgery. The secondary endpoints included

postoperative pain intensity, oxycodone consumption, and occurrence of adverse events up to 72

h after surgery.

Methods

<u>Ethics and registration</u>

This study (DoseRespKeta) was approved by the institutional review board of the Hospital

District of Southwest Finland (number: *103/1800/2016*) and the Finnish Medicines Agency

(FIMEA, KL 135/2016). The trial was registered before patient enrollment at clinicaltrials.gov

(NCT02994173; Principal investigator: TIS; Date of registration: September 11, 2017) and in the

EudraCT database (*2016-002887-14*; Principal investigator: TIS; Date of registration: October

12, 2016). No changes to methods were made after trial commencement. The detailed study

protocol is available upon request from the authors. Written informed consent was obtained from

the participants before inclusion to the study. This manuscript complies with the Consolidated

Standards of Reporting Trials guidelines.

<u>Patient population</u>

This two-center study was carried out at the T-hospital and TYKS ORTO units at Turku

University Hospital in Turku, Southwest Finland and the HUS Helsinki University Hospital's

Töölö Unit in Helsinki, Finland. One hundred and seven adult patients scheduled for elective

posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation under

general anesthesia were recruited between 6 February 2017 and 31 October 2019 (Fig 1).

Figure 1. DoseRespKeta trial structure and CONSORT 2009 flow diagram. CONSORT

indicates Consolidated Standards of Reporting Trials.

Patients with previous history of intolerance to a study drug, concomitant drug therapy with

strong opioids or strong cytochrome P450 3A4 or 2B6 inductor or inhibitors 2 weeks prior to

study, younger than 20 years and older than 80 years, BMI >35, sleep apnea or any other sleep

disorder, existing significant liver or kidney disease, history of alcoholism, drug abuse, and

psychological or other emotional problems likely to invalidate informed consent were excluded.

Patients were pre-screened by a preoperative care nurse. Potentially eligible subjects were

directed to investigators for further screening and information. ECVB and MP enrolled all

participants.

Study design, randomization, and blinding

A randomized, double-blind, controlled dose-response study design was used (Fig 1). The

allocation ratio was 1:1:1:1. Subjects were randomly assigned to one of four dosing groups (G)

for intravenous PCA:

- G1, oxycodone 1 mg ml^{-1} alone

- G2, oxycodone 1 mg ml^{-1} + S-ketamine 0.25 mg ml^{-1} (ratio 1:0.25)

- G3, oxycodone 1 mg ml^{-1} + S-ketamine 0.5 mg ml^{-1} (ratio 1:0.5),

- G4, oxycodone 1 mg ml^{-1} + S-ketamine 0.75 mg ml^{-1} (ratio 1:0.75).

An independent statistician created a computer-generated randomization list. The list was sent to

the local hospital pharmacy, which took care of assignment. Coded PCA reservoirs with no other

markings were delivered to the operation room by the pharmacy on the day of surgery to ensure

double blinding. Patients, researchers, and clinical staff were blinded to group allocation.

<u>Conduct of the study and anesthesia</u>

After providing written informed consent, patients learned to use the PCA system (CADD®-

Solis VIP and CADD-Legacy® PCA Pump Model 6300, Smiths Medical, Minneapolis, MN,

USA) and numerical rating scale (NRS; 0 denotes no pain, and 10 indicates the worst imaginable

pain). Preoperatively, all patients received 1000 mg of paracetamol orally. Routine anesthetic

monitoring included pulse oximetry, electrocardiography, invasive blood pressure via radial

artery cannulation, and body temperature measurement. General anesthesia was induced and

maintained with propofol (Propofol-Lipuro 20 mg ml^{-1}; B. Braun Melsungen AG, Melsungen,

Germany) and remifentanil (Remifentanil B. Braun 1 mg ml^{-1}; B. Braun Melsungen AG,

Melsungen, Germany) target-controlled infusions. Schnider- and Minto-effect-site models were

used for propofol and remifentanil, respectively.[17,18] No opioids other than remifentanil were

used before or during anesthesia. Rocuronium bromide (Esmeron 10 mg ml^{-1}; Merck Sharp &

Dohme B.V., BN Haarlem, The Netherlands) 0.4–0.6 mg kg^{-1} facilitated endotracheal intubation.

The depth of anesthesia (bispectral index BIS or entropy index) was targeted from 45 to 55 with

entropy (GE B850 Monitor Entropy Module, GE, Helsinki, Finland) or BIS monitor (The Philips

BIS module, Philips Medical Systems, Eindhoven, The Netherlands). Mean arterial pressure

(MAP) was maintained at 65–75 mmHg. Intravenous bolus doses of ephedrine and/or

noradrenaline infusion were administered if necessary. Local anesthetic was injected to the skin

incision area before incision (lidocaine 5 mg kg^{-1} c. adrenaline 5 μg kg^{-1}; Orion Pharma, Espoo,

Finland) and after wound closure (levobupivacaine 2.5 mg kg^{-1}; Chirocaine 2.5 mg ml^{-1}, AbbVie

S.r.l., Campoverde di Aprilia, Italy) as per hospital routines.

At the end of surgery, the PCA pump was attached to the intravenous line and activated. The first

dose of PCA solution was given just after the cessation of propofol and remifentanil infusions,

before patients woke up from anesthesia. As soon as the patient awoke, they were encouraged to

use PCA to treat postoperative pain if necessary. The starting dose of oxycodone (Oxycodone

Orion 10 mg ml^{-1}; Orion Pharma, Espoo, Finland) in the PCA solution was 2 mg with a lockout

interval of 5 min. When NRS was 4 or lower, the PCA oxycodone dose was decreased to 1 mg

(G1–G4). The study PCA dosing continued for 24 h from the end of surgery. Thereafter, the

PCA cassette was changed to only an oxycodone-containing solution (G1). The total duration of

PCA treatment was three days. Postoperative nausea and vomiting (PONV) were treated with

intravenous ondansetron and dehydrobenzperidol if necessary. Potential excessive unpleasant

psychotomimetic effects from S-ketamine (Ketanest-S 5 mg ml^{-1}; Pfizer Manufacturing Belgium

NV, Puurs, Belgium) were treated with 1 mg intravenous bolus of lorazepam.

<u>Measurements and data handling</u>

Heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, NRS (0–10) for pain

intensity at rest and upon movement, level of sedation with the Richmond Agitation-Sedation

scale (RASS), nausea, vomiting, pruritus, unpleasant dreams or any other adverse effect or

sensation thought to be caused by PCA, cumulative PCA pressings, or the doses given were

registered immediately after arrival in the recovery room and at the following time points: five,

30, 60 , 120, and 240 minutes and eight, 24, 48, and 72 hours later. Patients evaluated their pain

relief satisfaction (yes/no) at the end of postoperative days 1–3.

All clinical patient data were collected on individual case report forms. All data were

subsequently transferred to electronic format for exploratory data analysis.

<u>Primary and secondary outcomes</u>

The primary endpoint was cumulative oxycodone consumption at 24 h after surgery, the end of

period when three different ratios of S-ketamine were added to oxycodone PCA solution.

Secondary outcomes were NRS and RASS ratings, oxycodone consumption, PONV, pruritus,

and unpleasant dreams or other adverse effects.

Sample size calculation

Based on a previous study,[19] we calculated that 25 patients per group were necessary to

demonstrate a clinically significant 25% reduction in oxycodone consumption with a level of

significance of $P = 0.05$ and power of 80%.

Statistical analyses

The authors approved the statistical analysis plan before the analyses began. Explorative data

analysis was conducted before statistical inference by plotting and tabulating the data. Normality

assumptions were tested before analysis, using probit plots and the Shapiro–Wilk W-test.

Levene's test was used to evaluate homogeneity of variances.

The primary outcome measure, cumulative opioid consumption during the first 24 h is presented

as both median and interquartile range (IQR; Q1–Q3) and mean (SD). Cumulative opioid

consumption at 24, 48, and 72 h was analyzed by using a linear mixed model for repeated

measurements. The model included the following factors: PCA dosing groups G1–G4, age (as a

continuous covariate), age, gender, prior use of opioids (yes/no), prior use of gabapentinoids

(yes/no), cumulative amount of dose requests during PCA, and postoperative time (24, 48, and

72 h). In addition, the interaction with time and opioid consumption and prior use of weak

opioids was examined. Non-significant terms were excluded from the final model. An

unstructured covariance structure was used. Square-root transformation was used to fulfill

assumptions of the model. Studentized residuals were used to check assumptions.

To study pain burden, we analyzed if the mean change in NRS over time differed between the

groups during the first 24 hours postoperatively. A hierarchical linear mixed model was used

including time as a within-factor (with five time points), PCA dosing group as a between-factor,

and their interaction. The time factor was handled as categorical to estimate all possible shapes

of mean changes over time. NRS values were standardized before analysis by centering and

scaling to have a mean of zero and a SD of one. Effect sizes were computed as the eta squared

based on the H-statistic.[20] We also studied in a separate model, whether age, sex, weight, chronic

pain, and prior use of weak opioids or gabapentinoids affected the results. Differences in NRS

and sedation (measured with RASS) between the groups were evaluated at the end of post-

anesthesia care unit (PACU) treatment (t = 480 min) and at 24 h with a Kruskal–Wallis test.

Differences in postoperative nausea and vomiting, pruritus, and unpleasant dreams (yes/no)

among groups at 24, 48, and 72 h postoperatively were evaluated with ordinal logistic regression.

The effect of age, sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids on

the results were tested as covariate effects. To analyze the effect of adjuvant ketamine treatment

on these parameters, we included changes in parameters to the model during the previous 24 h.

Descriptive statistics are shown as means and SD when variables are normally distributed and

otherwise as medians and IRQs. Categorical variables are summarized as counts and

percentages. The statistical significance level was set to $P <0.05$. RStudio (version 1.0.153)[21]

with R (version 3.6.0)[22] and ggplot2 (version 2.2.1) were used for statistical analyses and

graphical presentations.

Results

A total of 231 patients were assessed for eligibility. 107 patients were recruited in the study (Fig

1B) between February 2017 and October 2019. Two patients withdrew their consent before

randomization and were excluded. Two patients were further excluded due to logistical reasons

before surgery. In one case, the operation plan was changed after randomization and this patient

was also excluded from the study. Two more patients withdrew consent during the first 24 h after

the start of intervention and were excluded from the final analysis. Thus, 25 patients in each of

the four groups were included in the analysis. Patient median age was 60 (28–78) years and 77%

were women. No significant differences in baselines characteristics were present among the

groups (Table 1).

Table 1. Perioperative Data and Characteristics of Patients Who Were Included in the Analysis.

	All	G1	G2	Standardized Differences Between G1 and G2	G3	Standardized Differences Between G1 and G3	G4	Standardized Differences Between G1 and G4
n	100	25	25		25		25	
Age, yr (median, range)	60 (28-78)[2]	56 (34-78)	62 (28-76)	0.214	60 (40-75)	0.433	62 (30-76)	0.329
Female/male, n (%)	45/55	11/14 (44%)[1]	11/14 (44%)	<0.001	12/13 (48%)	<0.001	11/14 (44%)	0.08
Body weight (kg)	77.7 (15.6)	77.7 (15.6)	74.9 (15.9)	0.215	79.0 (14.1)	0.278	77.0 (11.2)	0.156
BMI (kg/m^{-2})	26.9 (4.3)	26.6 (4.6)	27.3 (4.3)	0.003	26.9 (3.5)	0.152	26.8 (4.9)	0.063
Smoking (yes/no), n (%)	9/91	1/24 (4%)	3/22 (12%)	0.169	3/22 (12%)	0.298	2/23 (7.7%)	0.298
Previous chronic pain (yes/no), n (%)	15/85	22/3 (88%)[1]	19/6 (76%)	0.115	22/3 (88%)	0.316	22/3 (88%)	<0.001
Median [IRQ] preoperative pain intensity (NRS)	6 [4, 8]	6 [5, 7]	5 [5, 7]	0.1	7 [5. 8]	0.42	7 [5. 8]	0.023
Preoperative opioid (yes/no), n (%)	5/94	2/23 (8.0%)[1]	2/23 (8.0%)	0.169	0/25 (0%)	<0.001	1/24 (3.8%)	0.417
Preoperative gabapentinod (yes/no), n (%)	18/82	3/22 (12%)[1]	3/22 (12%)	0.22	7/18 (28%)	<0.001	5/20 (19%)	0.408
Diabetes (yes/no), n (%)	8/92	1/24 (4.0%)[1]	3/22 (12%)	0.169	1/25 (4.0%)	0.298	3/22 (11%)	<0.001
ASA physical status, n (%)				0.408		0.182		0.331
1	24	7 (28.0)	6 (24.0)		6 (24.0)		5 (20.0)	
2	66	17 (68.0)	15 (60.0)		17 (68.0)		17 (68.0)	
3	10	1 (4.0)	4 (16.0)		2 (8.0)		3 (12.0)	

Duration of surgery (min)	306 (94)	325 (89)	292 (64)	0.424	303 (125)	0.202	305 (89)	0.226
Propofol during surgery (mg kg^{-1})	37 (12)	39 (11)	36 (8)	0.259	35 (17)	0.26	36 (10)	0.248
Remifentanil during surgery (µg kg^{-1} min^{-1})	0.12 (0.05)	0.13 (0.06)	0.12 (0.04)	0.27	0.11 (0.04)	0.429	0.11 (0.04)	0.383

Data are mean (standard deviation) or [range) unless otherwise stated. Standardized difference is the difference in the mean of a

variable between 2 groups divided by an estimate of the standard deviation of that variable.[21]

G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine

0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled

intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).; n, number of non-missing value; BMI, body-mass index; IQR,

interquartile range; NRS, numerical rating scale; ASA, American Society of Anesthesiologists.

[1]Percentage of females or yes-answers

Opioid consumption

Cumulative oxycodone consumption was highest in group G1 and lowest in G4 (Fig 2, Table 2).

The median total oxycodone consumption during the first 24 h after surgery was 81.9 mg (IQR:

63.2–101), 74.1 mg (IQR: 62.1–86.1), 74.7 mg (IQR: 62.2–87.1), and 61.3 mg (IQR: 48.7–73.8)

in groups G1–G4, respectively. Postoperative cumulative oxycodone consumption was

significantly reduced in the group with the highest ketamine concentration (G4) compared with

the control group (G1): the mean difference was -21 mg (95% CI: -41 to -0.2, P = 0.048), -26

mg (95% CI: -55 to -6.2, P = 0.044) and -41 mg (95% CI: -68 to -14, P = 0.003) at 24, 48, and

72 h after surgery, respectively (Fig 2). There was no significant difference in time to dose

reduction from 2 mg to 1 mg PCA-bolus among groups (median [IQR]: 125 min [78–203], 127

min [82–174], 112 min [69–185] and 145 min [79–211] in groups G1–G4, respectively, P =

0.838).

Figure 2. Postoperative cumulative oxycodone consumption during the first 24 h in four patient-controlled analgesia (PCA) treatment groups (G1¬–G4). PCA, patient-controlled analgesia. Box plots show the median and 25–75th percentiles, and the whiskers indicate the minimum and maximum. Blue diamonds show the mean oxycodone consumption in each plot.

256 **Table 2**. Oxycodone consumption during the study after the beginning of PACU care

Time after PACU start	All (n=100)	G1 (n=25)	G2 (n=25)	G3 (n=25)	G4 (n=25)
60 min					
Mean (SD)	10.9 (4.2)	11.9 (3.4)	10.3 (3.9)	11.3 (4.2)	10.4 (5.1)
Median [IRQ]	10.0 [8.00, 14.0]	12.0 [8.0, 16.0]	10.0 [7.40, 14.0]	10.0 [8.0, 14.0]	12.0 [6.00, 14.0]
120 min					
Mean (SD)	19.2 (7.2)	21.2 (6.6)	18.2 (5.6)	20.0 (8.5)	17.3 (7.5)
Median [IRQ]	18.0 [14.0, 24.0]	21.0 [16.0, 25.0]	18.0 [16.0, 22.0]	18.0 [13.3, 24.0]	15.0 [12.0, 24.0]
240 min					
Mean (SD)	28.2 (12.5)	31.0 (13.0)	26.5 (9.3)	28.6 (14.8)	26.7 (12.6)
Median [IRQ]	26.8 [20.0, 35.0]	28.0 [25.0, 35.0]	26.6 [23.0, 34.0]	24.0 [18.0, 36.0]	26.0 [18.0, 34.0]
480 min					
Mean (SD)	35.5 [26.8, 46.3)	37.0 [31.0, 44.0)	34.0 [29.0, 49.0)	33.0 [26.0, 49.0)	36.0 [23.0, 45.0)
Median [IRQ]	37.6 (16.7)	39.6 (16.9)	36.4 (13.1)	39.1 (18.3)	35.5 (18.5)
24 h					
Mean (SD)	65.0 [46.8, 93.7)	65.0 [55.0, 104)	71.0 [48.0, 93.6)	71.0 [51.3, 93.0)	51.0 [42.0, 78.0)
Median [IRQ]	72.9 (36.5)	81.9 (47.6)	74.1 (30.7)	74.7 (31.8)	61.3 (32.3)
48 h					
Mean (SD)	117 (74.0)	137 (96)	118 (67.5)	121 (63.6)	90.8 (57.3)
Median [IRQ]	99.0 (65.2, 136)	118.0 (73.2, 147)	94.3 (73.2, 135)	112.0 (72.0, 130)	73.5 (52.0, 120)
72 h					

Mean (SD)	145 (95.6)	170 (123)	156 (97.7)	146 (67.0)	109 (73.3)
Median [IRQ]	127 [77.5, 170]	150 [88.2, 170]	128 [90.0, 189]	129 [97.0, 178]	89.0 [56.8, 147]

PACU, postoperative care unit, G1, Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone 1 mg/ml+ ketamine 0.75 mg/ml (n=25).

<u>Acute pain measurements during postoperative care</u>

Postoperative mean change in NRS measured at rest over the first 24 h differed significantly

between groups G4 and G1 (standardized effect size: 0.17, 95% CI: 0.013–0.32, P = 0.033), but

not between group G3 and G1 (standardized effect size: -0.097, 95% CI: -0.25–0.059, P = 0.223)

or G2 and G1 (standardized effect size -0.052, 95% CI: -0.21–0.10, P = 0.51) (Fig 3A). Age,

sex, weight, chronic pain, and prior use of weak opioids or gabapentinoids had no effect on the

results.

Figure 3. A) Patient-reported numerical rating scale (NRS) values at rest during the first 24 h in

four patient-controlled analgesia (PCA) treatment groups G1-G4. Box plots show the median

and 25–75th percentiles, and the whiskers indicate the minimum and maximum. (B) Risk ratios

(95% CI) for reporting NRS value 4 or higher. PACU, postoperative care unit; CI, confidence

interval.

To evaluate the effect of patient satisfaction, we analyzed the risk of having NRS >3 at rest at

different timepoints during PACU treatment. For this purpose, NRS values were dichotomized

depending on the pain level that patients experienced (NRS >3 or NRS ≤3). Although patient

satisfaction, measured by patient-reported NRS was smaller in groups G2–G4 than group G1 at

the end of PACU treatment, the finding was not statistically significant (Fig 3B).

<u>Postoperative sedation</u>

At arrival to PACU, median (IQR) RASS was -1 (-2–0), and all patients were cooperative. RASS

increased to 0 (-1 to 0) within the following 30 minutes. After 60 minutes, all patients were fully

awake (median [IQR] RASS: 0 [0, 0]), and they remained fully awake until the end of the study.

No significant differences in RASS scores were present between the groups during the 72-hour

follow-up (Table 3).

286   ----- **Table 3 here** -----

287   **Table 3.** Opioid related adverse events during the study.

Adverse effect		All	G1	G2	G3	G4
Sedation (RASS-scale)						
0 min		-1 [-2, 0][1]	-1 [-2, 0]	-1 [-3, 0]	-1 [-1,0]	-1 [-2, 0]
5 min		-1 [-2, 0]	-1 [-2, 0]	0 [-1, 0]	0 [0,-1]	-1 [-1, 0]
30 min		0 [0, 1]	0 [0,-1]	0 [-1, 0]	0 [-1, 1]	0 [-1, 0]
60 min		0 [0, 0]	0 [0,-1]	0 [0, 0]	0 [0, 0]	0 [0, 0]
2 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
4 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
8 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
24 hr		0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]	0 [0, 0]
PONV		n=100	n=23	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	2 (8)	3 (12)	6 (24)	5 (22)
	No (%)	82 (82)	23 (92)	22 (88)	19 (76)	18 (78)

48 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
	No (%)	90 (90)	21 (84)	24 (96)	20 (80)	20 (87)
72 hr	Yes (%)	11 (11)	2 (8)	1 (4)	5 (20)	3 (13)
	No (%)	90 (90)	21 (84)	24 (96)	20 (80)	20 (87)
Pruritus		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	16 (16)	4 (16)	7 (28)	4 (16)	1 (4)
	No (%)	84 (84)	21 (84)	18 (72)	21 (84)	24 (96)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
	No (%)	90 (90)	21 (84)	21 (84)	24 (96)	24
72 hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)
	No (%)	93 (93)	23(92)	24 (96)	23 (92)	23 (92)
Unpleasant dreams		n=100	n=25	n=25	n=25	n=25
24 hr	Yes (%)	9 (9)	2 (8)	2 (8)	2 (8)	3 (12)
	No (%)	91 (91)	23 (92)	23 (92)	23 (92)	22 (88)
48 hr	Yes (%)	10 (10)	4 (16)	4 (16)	1 (4)	1 (4)
	No (%)	90 (90)	21 (84)	21 (84)	24 (96)	24 (96)
72hr	Yes (%)	7 (7)	2 (8)	1 (4)	2 (8)	2 (8)
	No (%)	93 (93)	23(92)	24 (96)	23 (92)	23 (92)

[1] RASS-scale given as median [interquartile range]

RASS, Richmond Agitation-Sedation Scale; PONV, postoperative nausea and vomiting; G1,

Patient controlled intravenous oxycodone 1 mg/ml (n=25); G2, Patient controlled intravenous

oxycodone 1 mg/ml+ ketamine 0.25 mg/ml (n=25); G3, Patient controlled intravenous

oxycodone 1 mg/ml+ ketamine 0.5 mg/ml (n=25); G4, Patient controlled intravenous oxycodone

1 mg/ml+ ketamine 0.75 mg/ml (n=25).

<u>Opioid-related adverse effects</u>

Opioid-related adverse events during the study are summarized in Table 3. Nausea and vomiting

were the most frequent adverse events. At 24 h after PCA start, 16% of patients (n = 16) reported

nausea. Increasing ketamine dose seemed to increase the incidence of PONV, but the changes

were not statistically significant. Similarly, no differences were seen at the end of 48- and 72-h

follow-up. We analyzed these adverse effects further with logistic regression. Our results

indicate that preoperative weak opioid use increased the incidence of PONV significantly (odds

ratio: 9.23, 95% CI: 1.4–75). Adjuvant ketamine in PCA had no effect (odds ratio: 3.9, 95% CI:

0.68–4.7) on PONV, and after changing to normal PCA with only oxycodone at 24 h, the

incidence of PONV did not change (odds ratio: 0.53, 95% CI: 0.62–4.7).

At 24 h after PCA start, 16% of patients (n = 16) reported pruritus (Table 3). The PCA treatment

groups did not show statistically significant differences at any of the three time points (24, 48, or

72 h after the start of PCA). Similarly, the incidence of pruritus did not change after changing to

normal PCA with oxycodone only.

Nine patients (9%) reported nightmares or unpleasant dreams (Table 3). The groups showed no

difference in this regard, and the incidence did not change after changing to normal PCA with

oxycodone only. Age, sex, weight, chronic pain, and prior use of gabapentinoids had no effect on

the results.

<u>Other adverse effects</u>

There were no severe adverse effects. None of the patients developed respiratory insufficiency

requiring invasive or non-invasive ventilation during the 72-h study period. No rescue

medications were required during the study.

Discussion

This randomized, double-blind, placebo-controlled study evaluated the effect of adding

incremental doses of S-ketamine to oxycodone PCA in patients who underwent major lumbar

spinal fusion surgery. Our results demonstrate that patients who received oxycodone:S-ketamine

ratio 1:0.75 (a bolus containing oxycodone 1 mg + S-ketamine 0.75mg per ml) for postoperative

analgesia consumed significantly less oxycodone at 24 h postoperatively compared with

participants who received lower S-ketamine doses or oxycodone alone.

A significant beneficial effect in mean change in pain intensity at rest was seen in the group

receiving 0.75 mg ml^{-1} S-ketamine in oxycodone PCA compared with patients receiving lower

doses of ketamine or oxycodone alone. Cumulative oxycodone dose or adjunct S-ketamine did

not significantly influence postoperative nausea and vomiting. Occurrence of pruritus,

nightmares, or unpleasant dreams did not differ significantly among study groups.

Major spinal surgery is increasing in frequency and complexity. It is associated with severe

postoperative pain,[1] which is not easily amenable to regional anesthesia and requires a

multimodal approach. This is a crowded field of clinical research, with many previous studies

evaluating various single doses of ketamine with different opioids in many types of surgery. Yet,

there is little previous data that assesses the effect of adjunct ketamine to an IV opioid-PCA

exclusively after lumbar spinal fusion surgery in an opioid-naïve patient population. A recent

review and meta-analysis evaluated the effect of perioperative ketamine for analgesia in spine

surgery.[24] However, in most of the included trials, ketamine was administered intraoperatively

followed by postoperative IV-PCA or ketamine was given both as a pre-incisional bolus and as a

postoperative IV-PCA with a background infusion and a bolus on-demand.[25,26] This may confuse

evaluation of the analgesic effect of IV-PCA administration of ketamine with an opioid.

Additionally, the meta-analysis included patients undergoing lumbar microdiscectomy with

postoperative opioid IV-PCA.[27] It could be anticipated that pain after lumbar microdiscectomy is

less severe than after major lumbar spinal fusion surgery, and thus postoperative conditions are

not comparable. Furthermore, one previous study was an open-label trial[28] and another had only

female patients,[29] making it difficult to generalize results.

Previous studies have shown an opioid-sparing effect of intravenous low-dose ketamine after

spine surgery in opioid-dependent patients.[30, 31] Additionally, Loftus (2010) and Nielsen (2017)

showed that the benefit of ketamine increased with the amount of preoperatively administered

opioids.[30, 31] Recently Nielsen et al. (2019) showed that perioperative intravenous S-ketamine

reduced analgesic use and pain and improved labor market attachment of opioid-dependent

patients one year after spine surgery.[32] Another recent study further confirmed that postoperative

low-dose ketamine infusion reduced hydromorphone requirements for the first 24 h after spinal

fusion surgery in opioid-tolerant patients, but not in opioid-naïve patients.[33] However, it is

recognized that previous opioid use alters pain processing, and these patients typically require

higher opioid doses postoperatively. Thus, results of these studies cannot be directly applied to

all patients.

Although the effect of adjunct ketamine in the opioid-tolerant patient population after lumbar

fusion surgery is quite well established, the effect in the opioid-naïve population is less clear.

Additionally, the optimal dose of adjunct ketamine in an opioid IV-PCA is unknown. Data

indicating low incidence of ketamine-related adverse events (PONV and CNS adverse events)

has been consistent in previous studies.[11,12,33] Likewise, our study showed that adjunct S-

ketamine in oxycodone IV-PCA was well tolerated. There are several reports of ketamine's

beneficial effect on analgesia, opioid-sparing, and PONV in the postoperative period, without

increasing the risk for hallucinations. However, the opioid:ketamine ratio in IV-PCA in previous

studies was heterogeneous, ranging from 1:0.5 to 1:2.5, and these studies were also

heterogeneous in regard to the opioid used, anesthesia methodology, type of surgery, patient

population, and use of racemic- or S-ketamine.[34,35]

Our study has limitations. Our study was designed to detect a difference in 24 h cumulative

oxycodone consumption, which was the primary outcome. The beneficial effect of adjunct S-

ketamine in an oxycodone IV-PCA in reducing the 24 h oxycodone consumption did not

correlate with a reduction in opioid-related side effects, but this could be secondary to a lack of

power. On the other hand, the strengths of our study include that the patient population was

homogenous across study groups, consisting of adult men and women who underwent

posterolateral lumbar spine fusion with bilateral transpedicular screw instrumentation.

Postoperative analgesic consumption as a surrogate measure for pain has been criticized on the

basis of reports that it is skewed, where a minority of patients consume more than half of the

postoperative analgesic. A recent study encouraged reporting categorized parameters as more

clinically intuitive.[36] As discussed before, dichotomizing continuous measures leads to several

problems.[37] Previously, analgesic consumption has been analyzed with point estimates or

determining area under the curve, but both of these methods introduce considerable bias.

Statisticians recommend using a model-based approaches, which has been used here. Therefore,

both mean (SD) and median (IQR) have been reported. From a clinical perspective, it may be

unrealistic to achieve a totally pain-free state after major surgical trauma following surgery such

as instrumented lumbar spinal fusion. We think that IV-PCA enables the patient to titrate the

opioid to reach a certain individual, tolerable pain intensity level. Therefore, we consider that

changes in cumulative opioid consumption could serve as an acceptable surrogate for changes in

postoperative pain. However, we also evaluated the outcome by using risk ratios for pain

intensity NRS >3 as a surrogate for perioperative pain experience, and adjunct S-ketamine

seemed to decrease the likelihood of pain exceeding NRS >3.

Our study adds new data considering the optimal dose of adjunct S-ketamine to an oxycodone

IV-PCA after lumbar spinal fusion surgery. Because the oxycodone:S-ketamine ratio of 1:0.75

was not associated with increased adverse events, we suggest that future studies aimed at solving

the optimal opioid:S-ketamine ratio evaluate that dose and higher, possibly with pharmacokinetic

testing to characterize the dose-concentration-effect relationship.

In conclusion, IV-PCA containing adjunct S-ketamine with oxycodone at a ratio of 1:0.75 after

major lumbar spinal fusion surgery is effective in decreasing the total oxycodone consumption at

24 h after surgery. This oxycodone:S-ketamine ratio is also well tolerated. As previous studies

have mainly focused on intraoperative administration, even showing no analgesic effect of

intraoperative S-ketamine in opioid-naïve patients[38], this finding adds new data to the feasibility

of adjunct S-ketamine with oxycodone for postoperative pain management after major lumbar

spinal fusion surgery.

Funding: This work was supported by a governmental research grant from the Hospital District

of South-West Finland, Finland (#13821) (TIS).

Conflicts of interest: None.

Clinical Trial Number: clinicaltrials.gov #NCT02994173; Date of registration: September 11,

2017.

Abbreviated title: PCA with S-ketamine reduces postoperative opioid need

Author contributions:

Elina CV Brinck: This author helped in study planning, study conduct, data analysis, and writing
and revision of the manuscript.

Taru Virtanen and Venla Soini: These authors helped in study conduct, data analysis, and writing
and revision of the manuscript.

Sanna Mäkelä: This author helped in study conduct and revision of the manuscript.

Ville-Veikko Hynninen, Jukka Mulo, Urmas Savolainen, Juho Rantakokko, Kreu Maisniemi,
and Antti Liukas: These authors helped in study conduct

Klaus T. Olkkola, Vesa K Kontinen and Pekka Tarkkila: These authors helped in study design
and planning, study conduct, and revision of the manuscript.

Marko Peltoniemi This author helped in study design and planning, data analysis, and writing
and revision of the manuscript.

Teijo I. Saari: This author was the principal investigator. He helped in study design and planning,
data analysis, statistical inference, and writing and revision of the manuscript.

All authors accepted the final manuscript.

Keywords: postoperative; analgesia; PCA clinical advantages; opioid; ketamine

Acknowledgments

Eliisa Löyttyniemi, MSc, Institute of Biomedicine, University of Turku gave invaluable

statistical help. The nursing staff of K- and T-operating units, TYKS ORTO, and neurosurgical

wards at Turku University Hospital (Turku, Finland) and the staff of surgical ward 2 and the

anesthesia nurses of the Department of Orthopaedics and Trauma Surgery at Töölö Hospital

(Helsinki, Finland) are acknowledged for their support conducting the study. Sini Alanko, RN;

Toni Broman, RN; Virva Kuusisto, RN; and Jaana Virtanen, RN are thanked for their help at the

preoperative clinic. Tuula Eklund, RN; Ulla Simola, RN; and Saku Koskinen, RN are

acknowledged for their generous help with the patient data system. Local hospital pharmacies in

Turku and Helsinki University Hospitals are acknowledged, and ward pharmacists Anne

Honkanen, Kira Honkanen, Elina Luoto, Leea Rissanen, Mari Saalasti and Reija Silvennoinen

are thanked for fruitful collaboration.

References

1. Gerbershagen HJ, Aduckathil S, van Wijck AJM, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. *Anesthesiology*. 2013;118:934–944.

2. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. *Lancet*. 2006;367:1618–1625.

3. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. *Anesth Analg*. 2003;97:534–540.

4. Kurd MF, Kreitz T, Schroeder G, Vaccaro AR. The role of multimodal analgesia in spine surgery. *J Am Acad Orthop Surg*. 2017;25:260–268.

5. Cozowicz C, Bekeris J, Poeran J, Zubizarreta N, Schwenk E, Girardi F, et al. Multimodal pain management and postoperative outcomes in lumbar spine fusion surgery: a population-based cohort study. *Spine* (Phila Pa 1976). 2020;45:580–589.

6. McNicol E, Ferguson MC, Hudcova J. Patient-controlled analgesia versus non-patient controlled analgesia for postoperative pain. *Cochrane Database Syst Rev*. 2015;6:CD003348.

7. Dinges HC, Otto S, Stay DK, Bäumlein S, Waldmann S, Kranke P, et al. Side effect rates of opioids in equianalgesic doses via intravenous patient-controlled analgesia: a systematic review and network meta-analysis. *Anesth Analg*. 2019;129:1153–1162.

8. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin Pharmacokinet*. 2016;55:1059–1077.

9.   Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of

pain. *Cell.* 2009; 139:267–284.

10.   Hirota K, Lambert DG. Ketamine: new uses for an old drug? *Br J Anaesth.* 2011;107:123–

126.

11.   Woolf CJ. Pain amplification—a perspective on the how, why, when, and where of central

sensitization. *J Appl Biobehav Res.* 2018;23:e12124.

12.   Brinck EC, Tiippana E, Heesen M, Bell RF, Straube S, Moore RA, et al. Perioperative

intravenous ketamine for acute postoperative pain in adults. *Cochrane Database Syst Rev.*

2018;12:CD012033.

13.   Assouline B, Tramèr MR, Kreienbühl L, Elia N. Benefit and harm of adding ketamine to

an opioid in a patient-controlled analgesia device for the control of postoperative pain:

systematic review and meta-analyses of randomized controlled trials with trial sequential

analyses. *Pain.* 2016;157:2854–2864.

14.   Sveticic G, Gentilini A, Eichenberger U, Luginbühl M, Curatolo M. Combinations of

morphine with ketamine for patient-controlled analgesia: a new optimization method.

Anesthesiology. 2003;98:1195–11205.

15.   Sveticic G, Eichenberger U, Curatolo M. Safety of mixture of morphine with ketamine for

postoperative patient-controlled analgesia: an audit with 1026 patients. *Acta Anaesthiol*

Scand. 2005;49:870–875.

16.   Sveticic G, Farzanegan F, Zmoos P, Zmoos S, Eichenberger U, Curatolo M. Is the

combination of morphine with ketamine better than morphine alone for postoperative

intravenous patient-controlled analgesia? *Anesth Analg.* 2008;106:287–293, table of

contents.

17.   Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, et al. The

influence of age on propofol pharmacodynamics. *Anesthesiology.* 1999; 90:1502–1516.

18.   Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Billard V, et al. Influence of

age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model

development. *Anesthesiology.* 1997; 86:10–23.

19.   Lin T-F, Yeh Y-C, Lin F-S, Wang Y-P, Sun W-Z, Fan S-F. Effect of combining

dexmedetomidine and morphine for intravenous patient-controlled analgesia. *Br J Anaesth.*

2009;102:117–122.

20.   Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of

some recommended measures of effect size. *Trends Sport Sci.* 2014;1:19–25.

21.   RStudio Team. RStudio: Integrated Development Environment for R. 2020. Available at:

http://www.rstudio.com/. Accessed: 13 March, 2020.

22.   R Core Team. R: A Language and Environment for Statistical Computing. 2019. Available

at: http://www.r-project.org/. Accessed: 13 March 2020.

23.   Austin PC. Using the standardized difference to compare the prevalence of a binary

variable between two groups in observational research. *Commun Stat Simul Comput.*

2009;38:1228–1234.

24.   Pendi A, Field R, Farhan S-D, Eichler M, Bederman SS. Perioperative ketamine for

analgesia in spine surgery: a meta-analysis of randomized controlled trials. *Spine (Phila Pa*

1976). 2018; 43:E299–E307.

25.   Pacreu S, Fernández Candil J, Moltó L, Carazo J, Fernández Galinski S. The perioperative

combination of methadone and ketamine reduces post-operative opioid usage compared

with methadone alone. *Acta Anaesthiol Scand.* 2012;56:1250–1256.

26. Yeom JH, Chon M-S, Jeon WJ, Shim J-H. Perioperative ketamine with the ambulatory

elastometric infusion pump as an adjuvant to manage acute postoperative pain after spinal

fusion in adults: a prospective randomized trial. *Korean J Anesthesiol.* 2012;63:54–58.

27. Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and

morphine with ketamine for postoperative analgesia. *Can J Anaesth.* 1996;43:212–215.

28. Nitta R, Goyagi T, Nishikawa T. Combination of oral clonidine and intravenous low-dose

ketamine reduces the consumption of postoperative patient-controlled analgesia morphine

after spine surgery. *Acta Anaesthesiol Taiwan.* 2013;51:14–17.

29. Song JW, Shim JK, Song Y, Yang SY, Park SJ, Kwak YL. Effect of ketamine as an

adjunct to intravenous patient-controlled analgesia, in patients at high risk of postoperative

nausea and vomiting undergoing lumbar spinal surgery. *Br J Anaesth.* 2013;111:630–635.

30. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK. et al.

Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent

patients with chronic back pain undergoing back surgery. *Anesthesiology.* 2010;113:639–

646.

31. Nielsen RV, Fomsgaard JS, Siegel H, Martuseviicius R,Nikolajsen L, Dahl JB, al.

Intraoperative ketamine reduces immediate postoperative opioid consumption after spinal

fusion surgery in chronic pain patients with opioid dependency: a randomized, blinded

trial. *Pain.* 2017;158:463–470.

32. Nielsen RV, Fomsgaard JS, Nikolajsen L, Dahl JB, Mathiesen O. Intraoperative S-

ketamine for the reduction of opioid consumption and pain one year after spine surgery: a

randomized clinical trial of opioid-dependent patients. *Eur J Pain.* 2019;23:455–460.

33.   Boenigk K, Echevarria GC, Nisimov E, Bergen Granell AE von, Cuff GE, Wang J,

Atchabahian A. Low-dose ketamine infusion reduces postoperative hydromorphone

requirements in opioid-tolerant patients following spinal fusion: a randomised controlled

trial. *Eur J Anaesthesiol.* 2019;36:8–15.

34.   Wang L, Johnston B, Kaushal A, Cheng D, Zhu F, Martin J. Ketamine added to morphine

or hydromorphone patient-controlled analgesia for acute postoperative pain in adults: a

systematic review and meta-analysis of randomized trials. *Can J Anaesth.* 2016;63:311–

325.

35.   Carstensen M, Møller AM. Adding ketamine to morphine for intravenous patient-

controlled analgesia for acute postoperative pain: a qualitative review of randomized trials.

Br J Anaesth. 2010;104:401–406.

36.   Moore RA, Mhuircheartaigh RJN, Derry S, McQuay HJ. Mean analgesic consumption is

inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative

suggestion. *Eur J Anaesthesiol.* 2011;28:427–432.

37.   Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ.*

2006;332:1080.

38.   Brinck ECV, Maisniemi K, Kankare J, Tielinen L, Tarkkila P, Kontinen VK. Analgesic

effect of intraoperative intravenous S-ketamine in opioid-naïve patients after major lumbar

fusion surgery is temporary and not dose-dependent: a randomized, double-blind, placebo-

controlled clinical trial. *Anesth Analg.* 2021;132:69–79.

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction Background and objectives	2a	Scientific background and explanation of rationale	4
	2b	Specific objectives or hypotheses	4-5
Methods Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	-
Participants	4a	Eligibility criteria for participants	7
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7,9
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9-10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	-

Sample size	7a	How sample size was determined	10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	-
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	7
	11b	If relevant, description of the similarity of interventions	-
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	10-11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	-

Results

Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12
	13b	For each group, losses and exclusions after randomisation, together with reasons	12
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	12
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	12, table 1

Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	12
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	15, table 2
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	20-21
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	-
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	21

Discussion

Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	24
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	25
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	25

Other information

Registration	23	Registration number and name of trial registry	6
Protocol	24	Where the full trial protocol can be accessed, if available	1,6
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	8